B7-H3 (CD276): A Promising Target in Cancer Immunotherapy

What is B7-H3 (CD276)?

B7-H3 (also known as CD276) is a member of the B7 immune checkpoint family. It is:

• Highly expressed across a wide range of solid tumors.
• Low in normal tissues, making it an attractive therapeutic target.
• Associated with poor prognosis in many cancers.

Humans express two isoforms—2Ig and 4Ig—that may influence antibody binding and drug design. Understanding these isoforms is becoming increasingly important for biomarker development.

---

Latest Breakthroughs in 2025

1. Antibody–Drug Conjugates (ADCs) Lead the Way

Ifinatamab deruxtecan (I-DXd/DS-7300) received FDA Breakthrough Therapy designation in August 2025 for extensive-stage small-cell lung cancer (SCLC).

New data from the WCLC 2025 conference confirm its strong activity, positioning it as the first-in-class B7-H3 ADC.

ADCs are expected to be the near-term frontrunners for B7-H3–directed therapies.

2. CAR-T Cell Therapy Progress

• Early clinical trials (e.g., STRIvE-02) show feasible safety and measurable antitumor activity in solid tumors.
• Engineering strategies (armored CARs, regional delivery, dual-antigen logic) are being tested to improve persistence and selectivity.

3. Monoclonal Antibodies & Combinations

• Enoblituzumab (MGA271) has demonstrated immune remodeling in prostate cancer and is being evaluated in neoadjuvant settings.
• Combinations with checkpoint inhibitors, radiation, or anti-angiogenic drugs remain in development.

Why B7-H3 Matters Beyond Immunity?

Recent studies show that B7-H3 also drives tumor-intrinsic processes such as:

• Angiogenesis
• Metabolic reprogramming
• Invasion and metastasis
• Therapy resistance

This dual role (immune + tumor biology) makes B7-H3 an ideal combination therapy target.

Key Challenges Ahead

• Receptor unknowns: The true B7-H3 receptor is still unconfirmed.
• Biomarker development: Standardized assays (including isoform-specific detection) are needed.
• Safety balance: Low-level expression in normal tissues raises on-target/off-tumor concerns.

Outlook

With FDA support and a robust clinical pipeline, B7-H3 is transitioning from a “promising target” to a clinically validated pathway. Expect the next breakthroughs to clarify:

• Which tumor types benefit most.
• Which therapeutic formats (ADC, CAR-T, bispecifics) show the deepest efficacy.
• How biomarkers guide patient selection.

How RuntoGen Can Help

At RuntoGen, we support researchers and biotech developers exploring B7-H3 by offering:

B7-H3 overexpression cell lines for functional assays.

Knockout/knock-inmodels for mechanistic studies.

Custom cell line engineering services tailored to your project needs.

👉 Contact us today to accelerate your B7-H3 research and development.